Neil Everett Martin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 77 | 2023 | 11124 | 3.160 |
Why?
|
Androgen Antagonists | 20 | 2020 | 1377 | 1.240 |
Why?
|
Prostatectomy | 22 | 2020 | 1890 | 1.240 |
Why?
|
Prostate-Specific Antigen | 19 | 2023 | 2494 | 1.150 |
Why?
|
Testicular Neoplasms | 9 | 2024 | 804 | 1.040 |
Why?
|
Brachytherapy | 17 | 2021 | 1248 | 1.020 |
Why?
|
Radiosurgery | 6 | 2023 | 1329 | 0.970 |
Why?
|
Prostate | 11 | 2023 | 1774 | 0.810 |
Why?
|
Kallikreins | 3 | 2018 | 258 | 0.720 |
Why?
|
Radiation Oncology | 4 | 2019 | 555 | 0.690 |
Why?
|
Health Status Indicators | 2 | 2015 | 969 | 0.690 |
Why?
|
Tinnitus | 4 | 2023 | 195 | 0.570 |
Why?
|
Hearing Loss | 5 | 2023 | 765 | 0.530 |
Why?
|
Tosyl Compounds | 2 | 2014 | 113 | 0.530 |
Why?
|
Patient-Centered Care | 3 | 2016 | 1439 | 0.510 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1170 | 0.500 |
Why?
|
Quality Indicators, Health Care | 2 | 2015 | 1831 | 0.490 |
Why?
|
SEER Program | 18 | 2019 | 1508 | 0.480 |
Why?
|
Antineoplastic Agents, Hormonal | 5 | 2017 | 1524 | 0.470 |
Why?
|
Critical Pathways | 1 | 2017 | 476 | 0.470 |
Why?
|
RNA, Neoplasm | 2 | 2015 | 769 | 0.450 |
Why?
|
Medical Oncology | 2 | 2015 | 2265 | 0.450 |
Why?
|
Anilides | 2 | 2014 | 408 | 0.440 |
Why?
|
Flutamide | 1 | 2012 | 96 | 0.410 |
Why?
|
Health Status | 2 | 2015 | 4034 | 0.400 |
Why?
|
Radiotherapy | 5 | 2019 | 1533 | 0.380 |
Why?
|
Nitriles | 2 | 2014 | 956 | 0.380 |
Why?
|
Language | 1 | 2019 | 1471 | 0.350 |
Why?
|
Quality of Health Care | 3 | 2020 | 4371 | 0.340 |
Why?
|
Complementary Therapies | 1 | 2013 | 486 | 0.340 |
Why?
|
Male | 92 | 2024 | 350118 | 0.330 |
Why?
|
Adenocarcinoma | 6 | 2019 | 6364 | 0.320 |
Why?
|
Survivors | 3 | 2024 | 2291 | 0.300 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 3 | 2024 | 501 | 0.300 |
Why?
|
Bone Neoplasms | 3 | 2017 | 2529 | 0.290 |
Why?
|
Health Personnel | 1 | 2020 | 3218 | 0.280 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2013 | 1381 | 0.270 |
Why?
|
Neoplasm Staging | 17 | 2019 | 11031 | 0.260 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2938 | 0.260 |
Why?
|
Humans | 104 | 2024 | 744343 | 0.260 |
Why?
|
Testosterone | 2 | 2014 | 2420 | 0.250 |
Why?
|
Cancer Care Facilities | 3 | 2017 | 402 | 0.250 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2278 | 0.250 |
Why?
|
Aged | 65 | 2020 | 163280 | 0.250 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 89 | 0.240 |
Why?
|
Healthcare Disparities | 6 | 2016 | 3158 | 0.230 |
Why?
|
Neoplasms, Second Primary | 4 | 2021 | 1061 | 0.220 |
Why?
|
Neoplasms | 7 | 2022 | 21683 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
Travel | 2 | 2018 | 788 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.200 |
Why?
|
Exercise | 2 | 2015 | 5615 | 0.200 |
Why?
|
Middle Aged | 55 | 2024 | 213383 | 0.200 |
Why?
|
Health Behavior | 1 | 2013 | 2636 | 0.200 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3086 | 0.190 |
Why?
|
Particle Accelerators | 1 | 2021 | 173 | 0.190 |
Why?
|
Proportional Hazards Models | 16 | 2020 | 12354 | 0.190 |
Why?
|
Salvage Therapy | 3 | 2017 | 1275 | 0.190 |
Why?
|
Marital Status | 4 | 2015 | 437 | 0.180 |
Why?
|
Watchful Waiting | 3 | 2019 | 492 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.180 |
Why?
|
Palliative Care | 2 | 2017 | 3493 | 0.180 |
Why?
|
Databases, Factual | 10 | 2019 | 7729 | 0.170 |
Why?
|
Logistic Models | 11 | 2019 | 13408 | 0.170 |
Why?
|
Cisplatin | 5 | 2023 | 1662 | 0.170 |
Why?
|
Quality of Life | 4 | 2024 | 12804 | 0.160 |
Why?
|
PTEN Phosphohydrolase | 2 | 2015 | 1142 | 0.160 |
Why?
|
Anti-Anxiety Agents | 1 | 2021 | 390 | 0.160 |
Why?
|
Imidazoles | 1 | 2004 | 1206 | 0.160 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 290 | 0.160 |
Why?
|
Divorce | 1 | 2018 | 79 | 0.160 |
Why?
|
Academic Medical Centers | 3 | 2017 | 2759 | 0.160 |
Why?
|
Risk Assessment | 12 | 2020 | 23338 | 0.160 |
Why?
|
Speech Perception | 1 | 2022 | 489 | 0.150 |
Why?
|
Neuralgia | 1 | 2024 | 570 | 0.150 |
Why?
|
Antineoplastic Agents | 5 | 2024 | 13695 | 0.150 |
Why?
|
Diet | 1 | 2015 | 7939 | 0.140 |
Why?
|
Organizational Case Studies | 1 | 2017 | 299 | 0.140 |
Why?
|
Radiation Injuries | 2 | 2014 | 1180 | 0.140 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2022 | 685 | 0.140 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2023 | 3760 | 0.140 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2018 | 1770 | 0.140 |
Why?
|
Pancreatic Neoplasms | 2 | 2023 | 5256 | 0.140 |
Why?
|
Treatment Outcome | 19 | 2017 | 63114 | 0.130 |
Why?
|
Risk Factors | 21 | 2021 | 72290 | 0.130 |
Why?
|
Aged, 80 and over | 22 | 2019 | 57776 | 0.130 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8642 | 0.130 |
Why?
|
Smad4 Protein | 1 | 2015 | 163 | 0.130 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2021 | 806 | 0.120 |
Why?
|
United States | 26 | 2019 | 69872 | 0.120 |
Why?
|
Disease-Free Survival | 5 | 2017 | 6895 | 0.120 |
Why?
|
Immunohistochemistry | 5 | 2015 | 11366 | 0.120 |
Why?
|
Vasectomy | 1 | 2014 | 52 | 0.120 |
Why?
|
Paraffin Embedding | 1 | 2015 | 299 | 0.120 |
Why?
|
Time Factors | 11 | 2018 | 40075 | 0.120 |
Why?
|
Tissue Fixation | 1 | 2015 | 241 | 0.120 |
Why?
|
Osteopontin | 1 | 2015 | 296 | 0.120 |
Why?
|
Formaldehyde | 1 | 2015 | 353 | 0.110 |
Why?
|
Cyclin D1 | 1 | 2015 | 463 | 0.110 |
Why?
|
Gene Expression Profiling | 4 | 2017 | 9438 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2016 | 9239 | 0.110 |
Why?
|
Anus Neoplasms | 1 | 2016 | 332 | 0.110 |
Why?
|
Socioeconomic Factors | 6 | 2017 | 7785 | 0.110 |
Why?
|
Telephone | 1 | 2016 | 617 | 0.110 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.110 |
Why?
|
Prognosis | 11 | 2020 | 29063 | 0.110 |
Why?
|
Follow-Up Studies | 15 | 2019 | 39050 | 0.110 |
Why?
|
Health Status Disparities | 2 | 2014 | 1797 | 0.110 |
Why?
|
Urology | 1 | 2017 | 399 | 0.110 |
Why?
|
Rectum | 2 | 2014 | 904 | 0.100 |
Why?
|
Medically Uninsured | 2 | 2016 | 853 | 0.100 |
Why?
|
Superoxide Dismutase | 1 | 2015 | 597 | 0.100 |
Why?
|
Organs at Risk | 1 | 2014 | 346 | 0.100 |
Why?
|
Seminoma | 1 | 2013 | 137 | 0.100 |
Why?
|
Nephrectomy | 1 | 2018 | 1050 | 0.100 |
Why?
|
Stromal Cells | 1 | 2017 | 1355 | 0.100 |
Why?
|
Delphi Technique | 1 | 2014 | 778 | 0.100 |
Why?
|
Survival Rate | 7 | 2016 | 12788 | 0.100 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 415 | 0.100 |
Why?
|
Income | 3 | 2014 | 1913 | 0.100 |
Why?
|
Endoribonucleases | 1 | 2013 | 229 | 0.100 |
Why?
|
Community Health Services | 1 | 2016 | 650 | 0.100 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 548 | 0.100 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 390 | 0.100 |
Why?
|
Survival Analysis | 6 | 2018 | 10252 | 0.100 |
Why?
|
Treatment Refusal | 1 | 2014 | 421 | 0.090 |
Why?
|
Cohort Studies | 11 | 2020 | 40561 | 0.090 |
Why?
|
Predictive Value of Tests | 6 | 2018 | 15076 | 0.090 |
Why?
|
User-Computer Interface | 1 | 2017 | 1431 | 0.090 |
Why?
|
Geriatric Assessment | 2 | 2017 | 1372 | 0.090 |
Why?
|
Disease Progression | 6 | 2017 | 13284 | 0.090 |
Why?
|
beta Carotene | 1 | 2011 | 527 | 0.090 |
Why?
|
Prospective Studies | 7 | 2023 | 53288 | 0.090 |
Why?
|
Medical Informatics | 1 | 2017 | 745 | 0.090 |
Why?
|
Consensus | 2 | 2019 | 2959 | 0.090 |
Why?
|
Gene Fusion | 1 | 2012 | 371 | 0.080 |
Why?
|
Edema | 1 | 2013 | 789 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2020 | 2708 | 0.080 |
Why?
|
Sexual Behavior | 1 | 2019 | 2057 | 0.080 |
Why?
|
Enzyme Activation | 1 | 2015 | 3701 | 0.080 |
Why?
|
Antidepressive Agents | 1 | 2021 | 2838 | 0.080 |
Why?
|
Multivariate Analysis | 6 | 2019 | 12245 | 0.080 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1405 | 0.080 |
Why?
|
Retrospective Studies | 16 | 2023 | 77449 | 0.080 |
Why?
|
Hyperpigmentation | 1 | 2009 | 112 | 0.080 |
Why?
|
Cause of Death | 6 | 2018 | 3584 | 0.080 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2009 | 876 | 0.080 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2014 | 1205 | 0.080 |
Why?
|
Health Surveys | 1 | 2017 | 4037 | 0.080 |
Why?
|
Propensity Score | 3 | 2021 | 1781 | 0.070 |
Why?
|
Adult | 19 | 2024 | 214055 | 0.070 |
Why?
|
Genetic Association Studies | 2 | 2015 | 2703 | 0.070 |
Why?
|
Serine Endopeptidases | 1 | 2012 | 1072 | 0.070 |
Why?
|
Radiotherapy Dosage | 3 | 2023 | 2879 | 0.070 |
Why?
|
Anxiety | 1 | 2021 | 4297 | 0.070 |
Why?
|
Myocardial Infarction | 3 | 2013 | 11727 | 0.070 |
Why?
|
Age Factors | 7 | 2018 | 18370 | 0.070 |
Why?
|
Insurance Coverage | 2 | 2014 | 1901 | 0.070 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2013 | 1581 | 0.070 |
Why?
|
Alopecia | 1 | 2009 | 382 | 0.070 |
Why?
|
Odds Ratio | 5 | 2017 | 9849 | 0.070 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5751 | 0.060 |
Why?
|
Epithelial Cells | 1 | 2017 | 3690 | 0.060 |
Why?
|
Cost of Illness | 1 | 2015 | 1859 | 0.060 |
Why?
|
Vitamins | 1 | 2013 | 1622 | 0.060 |
Why?
|
Farnesyltranstransferase | 1 | 2004 | 76 | 0.060 |
Why?
|
Regression Analysis | 4 | 2016 | 6459 | 0.060 |
Why?
|
Incidence | 7 | 2015 | 20947 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3022 | 0.060 |
Why?
|
Weight Gain | 1 | 2014 | 2292 | 0.060 |
Why?
|
Urogenital System | 1 | 2023 | 86 | 0.060 |
Why?
|
Antioxidants | 1 | 2011 | 1663 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1790 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7722 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5391 | 0.060 |
Why?
|
Software | 1 | 2017 | 4443 | 0.060 |
Why?
|
Risk | 4 | 2019 | 9687 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2014 | 3474 | 0.050 |
Why?
|
Overweight | 1 | 2014 | 2371 | 0.050 |
Why?
|
Health Care Costs | 1 | 2016 | 3209 | 0.050 |
Why?
|
Trans-Activators | 1 | 2012 | 2924 | 0.050 |
Why?
|
Radiation Tolerance | 2 | 2016 | 486 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 6489 | 0.050 |
Why?
|
Insurance, Health | 1 | 2014 | 2494 | 0.050 |
Why?
|
Depression | 1 | 2021 | 7766 | 0.050 |
Why?
|
Aspirin | 1 | 2013 | 3282 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5137 | 0.050 |
Why?
|
Sensation Disorders | 1 | 2022 | 155 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 4034 | 0.050 |
Why?
|
Coronary Artery Bypass | 1 | 2010 | 2289 | 0.050 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1641 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2014 | 5021 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2017 | 4468 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11524 | 0.050 |
Why?
|
Fiducial Markers | 1 | 2021 | 136 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2015 | 13033 | 0.040 |
Why?
|
Coronary Disease | 1 | 2014 | 6077 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2015 | 2971 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 35421 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2004 | 2274 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4567 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3749 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2459 | 0.040 |
Why?
|
Tumor Burden | 2 | 2015 | 1915 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3255 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4838 | 0.040 |
Why?
|
Pharmacogenetics | 1 | 2022 | 675 | 0.040 |
Why?
|
Speech | 1 | 2022 | 540 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2017 | 3920 | 0.040 |
Why?
|
Obesity | 2 | 2024 | 12745 | 0.040 |
Why?
|
Heart Failure | 2 | 2011 | 10900 | 0.040 |
Why?
|
Organ Size | 2 | 2013 | 2252 | 0.040 |
Why?
|
Marriage | 1 | 2018 | 339 | 0.030 |
Why?
|
Cryotherapy | 1 | 2017 | 155 | 0.030 |
Why?
|
Educational Status | 2 | 2014 | 2540 | 0.030 |
Why?
|
Stents | 2 | 2023 | 3280 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 288 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2017 | 5078 | 0.030 |
Why?
|
Data Display | 1 | 2016 | 182 | 0.030 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2014 | 30 | 0.030 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 441 | 0.030 |
Why?
|
Goserelin | 1 | 2014 | 129 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1624 | 0.030 |
Why?
|
Community Health Centers | 1 | 2017 | 430 | 0.030 |
Why?
|
Minority Health | 1 | 2014 | 87 | 0.030 |
Why?
|
Survival | 1 | 2013 | 163 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 2015 | 455 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2021 | 2480 | 0.030 |
Why?
|
Leuprolide | 1 | 2014 | 321 | 0.030 |
Why?
|
Epithelium | 1 | 2017 | 1679 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2017 | 764 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 553 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2014 | 15295 | 0.030 |
Why?
|
Signal Transduction | 1 | 2015 | 23403 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10943 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1637 | 0.020 |
Why?
|
Demography | 1 | 2016 | 1656 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1654 | 0.020 |
Why?
|
Urethra | 1 | 2013 | 408 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 841 | 0.020 |
Why?
|
Neoadjuvant Therapy | 2 | 2013 | 2728 | 0.020 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2013 | 233 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2015 | 1364 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3558 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16365 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2948 | 0.020 |
Why?
|
Young Adult | 4 | 2021 | 56430 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2021 | 2149 | 0.020 |
Why?
|
Waist Circumference | 1 | 2013 | 917 | 0.020 |
Why?
|
Iodine Radioisotopes | 1 | 2013 | 1032 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2017 | 8428 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1534 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1769 | 0.020 |
Why?
|
Female | 9 | 2016 | 380194 | 0.020 |
Why?
|
Lymphoma, Follicular | 1 | 2013 | 435 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2297 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 3479 | 0.020 |
Why?
|
Radiometry | 1 | 2013 | 800 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 9959 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2004 | 16689 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1940 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2864 | 0.020 |
Why?
|
Angioplasty | 1 | 2010 | 364 | 0.020 |
Why?
|
History, 20th Century | 1 | 2015 | 2740 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 2924 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3616 | 0.020 |
Why?
|
Qualitative Research | 1 | 2016 | 2682 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3507 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2618 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2012 | 1179 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 1788 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4851 | 0.020 |
Why?
|
Physical Examination | 1 | 2013 | 1237 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.020 |
Why?
|
Bone and Bones | 1 | 2017 | 2575 | 0.020 |
Why?
|
Body Mass Index | 2 | 2014 | 12720 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2014 | 1411 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17446 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5952 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2014 | 6365 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2015 | 2266 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 15519 | 0.020 |
Why?
|
Up-Regulation | 1 | 2013 | 4217 | 0.020 |
Why?
|
Boston | 1 | 2017 | 9313 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 29786 | 0.010 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2014 | 1209 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2118 | 0.010 |
Why?
|
Biopsy | 1 | 2015 | 6756 | 0.010 |
Why?
|
Genome, Human | 1 | 2016 | 4420 | 0.010 |
Why?
|
Body Weight | 1 | 2014 | 4669 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3200 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12261 | 0.010 |
Why?
|
Poverty | 1 | 2014 | 2660 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8663 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5172 | 0.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2013 | 1596 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 7023 | 0.010 |
Why?
|
Health Policy | 1 | 2013 | 2661 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3778 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 13881 | 0.010 |
Why?
|
Registries | 1 | 2016 | 8089 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10397 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 85781 | 0.010 |
Why?
|
Animals | 1 | 2011 | 168757 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10388 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 12951 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2011 | 12026 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2013 | 7279 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10638 | 0.010 |
Why?
|
Child | 1 | 2021 | 77709 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15165 | 0.000 |
Why?
|